TARRYTOWN, N.Y. - The U.S. Food and Drug Administration (FDA) has expanded the approval for Dupixent® (dupilumab) to include adolescent patients aged 12 to 17 with inadequately controlled chronic ...

TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...

13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab ...

Looking for a new TV? Then there’s no doubt you’re considering and OLED TV. The class-leading television technology, which stands for Organic Light Emitting Diode, has captured the ...

This is the ninth indication for DUPIXENT ® in Canada and its second in gastroenterology 1 Expanded indication marks second disease for which DUPIXENT ® is approved in children this young in the ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Sanofi’s (Euronext: SAN) mega blockbuster drug Dupixent (dupilumab) as an add-on maintenance ...

The LIBERTY-CUPID C study enrolled CSU patients aged six years and older who remained symptomatic despite standard-of-care (SOC) antihistamines and were not previously treated with Novartis NVS ...

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous ...

Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) on Wednesday announced that a Phase 3 trial for their blockbuster asthma therapy Dupixent for a skin condition known as bullous pemphigoid succeeded ...